Drug intelligence / Profile preview

ab375

Development stage: Preclinical
Lead developer: Arcus Biosciences
Modality: Small Molecules

Overview

AB375 is a small molecule inhibitor targeting **c-Kit** (also known as stem cell growth factor receptor), under development by Arcus Biosciences. It is being investigated primarily for its potential therapeutic effects in conditions involving mast-cell activation, such as **anaphylaxis** and **inflammation**. As of the latest available information, AB375 has reached the **preclinical** stage of development and is distinguished by its high selectivity for the KIT receptor, which plays a key role in the regulation of mast cell activity[1][5].

Other names: AB375AB-375AB 375

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on ab375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ab375.

Explore the full profile